Stuart L. Cantor completed his Ph.D in pharmaceutical sciences at the University of Maryland School of Pharmacy. Dr. Cantor is a scientist with deep expertise in the product development and commercialization of both pharmaceutical and nutraceutical products, has extensive experience assessing all aspects of healthcare intellectual property, and doing business development for start-up companies.
His expertise lies in the development of tablets and capsules, controlled release technologies, and orally disintegrating tablets (ODTs). He previously worked for a pharmaceutical start-up company where he developed several nutraceutical products which were licensed to and commercialized by Bristol Myers Squibb.
Dr. Cantor has published 58 articles in the nutraceutical and pharmaceutical fields dealing with various R&D, processing, ingredient functionality/chemistry, and regulatory topics. He was a pharmaceutical formulation scientist at the Food & Drug Administration (FDA), where he developed solid oral dosage forms (tablets and capsules) and conducted analytical work to support various regulatory issues. He is currently working as a CMC consultant at Agios Pharmaceuticals and previously consulted at Proteus Digital Health where he was involved with developing drug and medical device combination products.